PIK3CG and neoplasm: Within the PAM signaling pathway, PI3K is a primary drug target for cancer treatment since its hyperactivity is strongly associated with tumor progression, enhanced tumor microvascular formation, and increased cancer cell invasiveness (Liu et al., 2020a).